BioNexus Gene Lab Corp. Files 8-K, Changes Fiscal Year

TL;DR

BioNexus Gene Lab Corp. changed its fiscal year end to 12/31, filed 9/5/24.

AI Summary

BioNexus Gene Lab Corp. filed an 8-K on September 5, 2024, reporting a change in its fiscal year end to December 31st. This filing also includes financial statements and exhibits, with the date of the earliest event reported being September 4, 2024. The company is incorporated in Wyoming and its principal business address is in Kuala Lumpur.

Why It Matters

A change in fiscal year end can impact reporting schedules and financial comparisons for investors. This filing provides updated information on the company's financial reporting structure.

Risk Assessment

Risk Level: low — This filing is primarily administrative, reporting a change in fiscal year end and including standard financial exhibits, with no immediate indication of significant operational or financial distress.

Key Numbers

• 001-41750 — SEC File Number (Identifies the company's filing history with the SEC.)
• 0001737523 — Central Index Key (Unique identifier for the company in the SEC's EDGAR system.)

Key Players & Entities

• BioNexus Gene Lab Corp. (company) — Registrant
• Wyoming (jurisdiction) — State of incorporation
• September 5, 2024 (date) — Date of report
• September 4, 2024 (date) — Date of earliest event reported
• 1231 (date) — Fiscal year end

FAQ

Filing Documents

• bglc_8k.htm (8-K) — 26KB
• bglc_ex31.htm (EX-3.1) — 34KB
• 0001477932-24-005537.txt ( ) — 196KB
• bglc-20240904.xsd (EX-101.SCH) — 6KB
• bglc-20240904_lab.xml (EX-101.LAB) — 15KB
• bglc-20240904_cal.xml (EX-101.CAL) — 1KB
• bglc-20240904_pre.xml (EX-101.PRE) — 10KB
• bglc-20240904_def.xml (EX-101.DEF) — 2KB
• bglc_8k_htm.xml (XML) — 4KB

03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On September 4, 2024, the Board of Directors (the " Board ") of BioNexus Gene Lab Corp. (the "Company") adopted amended and restated bylaws of the Company (the " Amended and Restated Bylaws "), effective immediately. The Amended and Restated Bylaws amends Article II, Section 2.7 of the Bylaws to revise the quorum requirement for a meeting of stockholders from a majority of the outstanding shares of the Company entitled to vote, represented in person or by proxy, to one-third of the outstanding shares of the Company entitled to vote, represented in person or by proxy. The foregoing description of the Amended and Restated Bylaws does not purport to be complete and is qualified in its entirety by reference to the Amended and Restated Bylaws, which are filed as Exhibit 3.1 hereto and are incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit Description 3.1 The Amended and Restated Bylaws 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioNexus Gene Lab Corp. Date: September 5, 2024 By: /s/ Su-Leng Tan Lee Name: Su-Leng Tan Lee Title: Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR